Anna Herland

Prof. Anna Herland

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TPTae-Eun Park
Tae-Eun Park
Nur MustafaogluNur Mustafaoglu
Nur Mustafaoglu
AHAnna Herland
Anna Herland
RHRyan Hasselkus
Ryan Hasselkus
RMRobert Mannix
Robert Mannix
DIDonald E Ingber
Donald E Ingber
The high selectivity of the human blood-brain barrier (BBB) restricts delivery of many pharmaceuticals and therapeutic antibodies to the central nervous system. Here, we describe an in vitro microfluidic organ-on-a-chip BBB model lined by induced pluripotent stem cell-derived human brain microvascular endothelium interfaced with primary human brain astrocytes and pericytes that recapitulates the high level of barrier function of the in vivo human BBB for at least one week in culture. The endothelium expresses high levels of tight junction proteins and functional efflux pumps, and it displays selective transcytosis of peptides and antibodies previously observed in vivo. Increased barrier functionality was accomplished using a developmentally-inspired induction protocol that includes a period of differentiation under hypoxic conditions. This enhanced BBB Chip may therefore represent a new in vitro tool for development and validation of delivery systems that transport drugs and therapeutic antibodies across the human BBB.

24 January 2015 in Annual Review of Pathology: Mechanisms of Disease
Verified
Journal Article
Closed access
KBKambez H. Benam
Kambez H. Benam
SDStephanie Dauth
Stephanie Dauth
BHBryan Hassell
Bryan Hassell
AHAnna Herland
Anna Herland
AJAbhishek Jain
Abhishek Jain
DIDonald E Ingber
Donald E Ingber
The ultimate goal of most biomedical research is to gain greater insight into mechanisms of human disease or to develop new and improved therapies or diagnostics. Although great advances have been made in terms of developing disease models in animals, such as transgenic mice, many of these models fail to faithfully recapitulate the human condition. In addition, it is difficult to identify critical cellular and molecular contributors to disease or to vary them independently in whole-animal models. This challenge has attracted the interest of engineers, who have begun to collaborate with biologists to leverage recent advances in tissue engineering and microfabrication to develop novel in vitro models of disease. As these models are synthetic systems, specific molecular factors and individual cell types, including parenchymal cells, vascular cells, and immune cells, can be varied independently while simultaneously measuring system-level responses in real time. In this article, we provide some examples of these efforts, including engineered models of diseases of the heart, lung, intestine, liver, kidney, cartilage, skin and vascular, endocrine, musculoskeletal, and nervous systems, as well as models of infectious diseases and cancer. We also describe how engineered in vitro models can be combined with human inducible pluripotent stem cells to enable new insights into a broad variety of disease mechanisms, as well as provide a test bed for screening new therapies.

6 November 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KJKyung-Jin Jang
Kyung-Jin Jang
MOMonicah A. Otieno
Monicah A. Otieno
JRJaney Ronxhi
Janey Ronxhi
HLHeng-Keang Lim
Heng-Keang Lim
LELorna Ewart
Lorna Ewart
GHGeraldine A. Hamilton
Geraldine A. Hamilton
A rat, dog, and human Liver-Chip designed using microengineered Organs-on-Chips technology recapitulates species-specific drug toxicities.

27 January 2020 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
AHAnna Herland
Anna Herland
BMBen Maoz
Ben Maoz
DDDebarun Das
Debarun Das
MSMahadevabharath R. Somayaji
Mahadevabharath R. Somayaji
RPRachelle Prantil-Baun
Rachelle Prantil-Baun
DIDonald E Ingber
Donald E Ingber

1 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AHAnna Herland
Anna Herland
AMAndries van der Meer
Andries van der Meer
EFEdward A. FitzGerald
Edward A. FitzGerald
TPTae-Eun Park
Tae-Eun Park
JSJelle J. F. Sleeboom
Jelle J. F. Sleeboom
DIDonald E Ingber
Donald E Ingber
Neurovascular inflammation is a major contributor to many neurological disorders, but modeling these processes in vitro has proven to be difficult. Here, we microengineered a three-dimensional (3D) model of the human blood-brain barrier (BBB) within a microfluidic chip by creating a cylindrical collagen gel containing a central hollow lumen inside a microchannel, culturing primary human brain microvascular endothelial cells on the gel’s inner surface, and flowing medium through the lumen. Studies were carried out with the engineered microvessel containing endothelium in the presence or absence of either primary human brain pericytes beneath the endothelium or primary human brain astrocytes within the surrounding collagen gel to explore the ability of this simplified model to identify distinct contributions of these supporting cells to the neuroinflammatory response. This human 3D BBB-on-a-chip exhibited barrier permeability similar to that observed in other in vitro BBB models created with non-human cells, and when stimulated with the inflammatory trigger, tumor necrosis factor-alpha (TNF-α), different secretion profiles for granulocyte colony-stimulating factor (G-CSF) and interleukin-6 (IL-6) were observed depending on the presence of astrocytes or pericytes. Importantly, the levels of these responses detected in the 3D BBB chip were significantly greater than when the same cells were co-cultured in static Transwell plates. Thus, as G-CSF and IL-6 have been reported to play important roles in neuroprotection and neuroactivation in vivo, this 3D BBB chip potentially offers a new method to study human neurovascular function and inflammation in vitro, and to identify physiological contributions of individual cell types.

27 January 2020 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
RNRichard Novak
Richard Novak
MIMiles Ingram
Miles Ingram
SMSusan Marquez
Susan Marquez
DDDebarun Das
Debarun Das
ADAaron Delahanty
Aaron Delahanty
DIDonald E Ingber
Donald E Ingber